Thanks for the information Dew, much appreciated. Interested to hear your take on the possibility of significantly reduced adverse effects with a new treatment option. If you set aside patient compliance and efficacy as roughly equal (oversimplification, of course), do you think a preference towards lack of potential hepatoxicity, immune function impairment, etc, might be enough to make a new treatment more commercially viable?
Obviously hypotheticals, but hey, I'm not trying to sell a company to anyone on this board. Just interested in different opinions and trains of thought. Appreciate the GILD folks here letting me crash the party for a few minutes.
News 
Market Data 
Discover 
